Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 41

Results For "Score"

932 News Found

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
News | October 31, 2025

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body


FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics
News | October 31, 2025

FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics

The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories


EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
Clinical Trials | October 31, 2025

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1


Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions
Clinical Trials | October 31, 2025

Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions

New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris


Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
News | October 30, 2025

Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US

Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs


Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM
News | October 30, 2025

Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM

Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives


FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma
Drug Approval | October 29, 2025

FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma

The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability